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Abstract: By examining the role research has played in
eradication or regional elimination initiatives for three
viral diseases—smallpox, poliomyelitis, and measles—we
derive nine cross-cutting lessons applicable to malaria
eradication. In these initiatives, some types of research
commenced as the programs began and proceeded in
parallel. Basic laboratory, clinical, and field research all
contributed notably to progress made in the viral
programs. For each program, vaccine was the lynchpin
intervention, but as the programs progressed, research
was required to improve vaccine formulations, delivery
methods, and immunization schedules. Surveillance was
fundamental to all three programs, whilst polio eradica-
tion also required improved diagnostic methods to
identify asymptomatic infections. Molecular characteriza-
tion of pathogen isolates strengthened surveillance and
allowed insights into the geographic source of infections
and their spread. Anthropologic, sociologic, and behav-
ioural research were needed to address cultural and
religious beliefs to expand community acceptance. The
last phases of elimination and eradication became
increasingly difficult, as a nil incidence was approached.
Any eradication initiative for malaria must incorporate
flexible research agendas that can adapt to changing
epidemiologic contingencies and allow planning for
posteradication scenarios.
Introduction
Despite a previous global eradication campaign (1955–1969),
malaria continues to be a major public health problem. Faced with
hundreds of millions of malaria cases annually and nearly a million
deaths, the international community is renewing efforts to
eradicate this disease. But, initiatives for national or regional
elimination or global eradication of any disease represent complex
efforts that consume vast financial, health services, and infra-
structural resources and require decades of commitment. Such
programs demand sound scientific underpinnings and manage-
ment structures that can adapt to changing epidemiologic scenes
and can learn from the experiences of previous programs. Herein
we describe three viral disease elimination/eradication efforts
whose research agendas offer lessons for malaria scientists and
public health program managers. The disease elimination
programs we consider are smallpox (the one human infectious
disease successfully eradicated), poliomyelitis (transmission of wild-
type 2 poliovirus was interrupted globally since 1999, although
transmission of types 1 and 3 continues in several countries), and
measles (whose transmission has been eliminated in the Americas
and in several countries worldwide). Each author has participated
in one or more of these eradication/elimination initiatives and
some also have experience in malaria research.
Throughout this article we use the following terms to denote
progressive decreases in the extent of human disease and
transmission of agent, as a result of deliberate interventions [1].
‘‘Control’’ is the reduction of incidence of a disease to an arbitrary
level whereupon it is no longer a public health priority.
‘‘Elimination’’ is the interruption of transmission of the pathogen
when disease incidence becomes zero in a population within a
large defined geographic area (e.g., one or more countries). A
caveat in measles and polio elimination initiatives is that imported
cases may appear in a country without indigenous transmission,
i.e., a country that has achieved elimination. Elimination is
considered to remain intact, so long as the importations are
contained and do not ignite anew extended indigenous transmis-
sion. Finally, ‘‘eradication’’ signifies the interruption of transmis-
sion of a pathogen worldwide and a reduction in disease incidence
to zero; this assumes that surveillance systems could detect
transmission, if any. Theoretically, eradication should obviate
the need for further control measures other than surveillance (as
with smallpox).
Aside from the common requirements for adequate resource
commitment, broad advocacy and political will relevant to all
disease eradication initiatives, there are biologic and epidemiologic
factors that specifically affect the feasibility of eradication of
smallpox, polio, measles, and malaria. Table 1 summarizes these
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salient factors. Table 2 provides illustrative examples in which
research played an important role in the eradication of smallpox,
the near-eradication of polio, and the elimination of measles from
the Americas and some other countries. From these experiences,
lessons were learned that are applicable to the Malaria Eradication
Program and that should, we believe, be incorporated in the
Malaria Eradication Research Agenda (malERA) described in this
Supplement.
Lesson 1. Research Should Accompany
Elimination/Eradication Efforts from the Outset
The foremost lesson learned from eradication/elimination
efforts for viral diseases is that a flexible research agenda must
be initiated early, prior to or concomitant with the launch of
eradication interventions.
Smallpox
Since 1959, when the World Health Assembly (WHA) resolved
to undertake global smallpox eradication, research played an
integral role in every facet of its implementation [2]. Without the
products of field and laboratory research and their incorporation
into the program, eradication would not have been achieved.
Research improved vaccine production methods to assure the
universal availability of potent, heat-stable products [3,4] and
provided improved instruments and methods for performing
vaccination [5,6]. Field studies yielded new insights into the
epidemiologic behaviour of smallpox under differing circumstanc-
es and identified optimal preventive and containment methods for
control, elimination, and eradication [2,7–10].
Between 1959 and 1966, progress in smallpox eradication was
limited. Then, in 1966 the WHA intensified the effort by allocating
US$2.4 million for the program. An overall strategy was
formulated that included vaccination of 80% of the population
in each country using vaccines of assured potency and establish-
ment in all countries of a weekly reporting system from all health
units with plans to vaccinate contacts and neighbours of all cases to
stop each outbreak rapidly—an approach termed ‘‘surveillance-
containment’’ [11]. In 1967, 43 countries reported 132,000 cases
Summary Points
N Lessons from the smallpox, poliomyelitis, and measles
eradication/elimination initiatives (in particular, the
importance of starting laboratory, clinical, and field
research early in the program and continuing research in
parallel) should be incorporated into any malaria
eradication initiative from the onset
N Vaccines are likely to be the lynchpin interventions of
elimination/eradication programs, but ongoing research
will be needed to improve formulations, delivery, and
immunization schedules
N Surveillance will be critical throughout any elimination/
eradication initiative, coupled with improved diagnostic
methods to detect asymptomatic infections and low
rates of transmission
N Because socio-cultural, religious, and local politics can
impede eradication efforts, it is prudent to support
research into improving ways to communicate effective-
ly with local populations about the disease and the
interventions to eradicate it
N A cross-cutting theme among the viral disease programs
is that interrupting the last vestiges of transmission is
particularly problematic and requires allocation of many
resources including support for focused ‘‘last kilometre’’
research activities
Table 1. A comparison of the inherent salient features of smallpox, polio, measles, and malaria infections that favour or impede
elimination of the disease and the most effective past and current interventions.
Feature Smallpox Polio Measles Malaria
Disease syndrome is
recognized by the public
Yes Yes (paralytic form) Yes Variable
Extent of clinical
expression
100% ,1% (many subclinical and
nonparalytic cases)
,100% Often low
Specificity of the clinical
disease
High High for paralytic disease;




2: V. major (high case fatality) and
V. minor (low case fatality)
3 1 5a
Reservoir Humans Humans Humans Humans (except for
P. knowlesi)a
Transmissibility Usually low to moderate High Very high Variable
Seasonality Yes (regional) Yes (regional) Yes (regional) Often
Incubation period (d) 12–14 6–20 9–13 ,12
Immunity follows a
single clinical infection
Yes Yes (type specific) Yes Nob






aP. falciparum, P. vivax, P. malariae, and P. ovale are restricted to human hosts. P. knowlesi, which mainly infects nonhuman primates, can also cause disease in humans
following natural transmission.
bHowever, the development of immunity against clinical disease follows repeated infections.
ACT, artemisinin combination therapy; IPTi, intermittent preventive treatment in infants; IPTp, intermittent preventive treatment in pregnancy; IRS, indoor residual
spraying; ITN, insecticide treated bednets.
doi:10.1371/journal.pmed.1000405.t001
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of smallpox, but studies revealed that only 1%–2% of cases were
being reported at that time. [12]. The goal was to stop smallpox
transmission in 10 years. The last case occurred 10 years, 11
months, and 26 days later.
Polio
Poliomyelitis (polio) was one of six childhood diseases targeted
for control in 1974 by the World Health Organization (WHO)
through the Expanded Program on Immunization (EPI).
Research during the Smallpox Eradication Program confirmed
the feasibility of coadministering multiple antigens and experi-
ence was acquired in managerial aspects of vaccine delivery and
disease surveillance [13]. However, polio outbreaks continued in
low- and middle-income countries, mostly tropical/subtropical,
despite routine administration of trivalent oral polio vaccine
(tOPV) [14].
In 1980, Brazil began coordinated mass administration of tOPV
(supplementary immunization activity) twice annually to all
children ,5 years of age [15], and a dramatic reduction of
paralytic polio incidence ensued. Encouraged by the success of this
strategy, in 1985 the Pan American Health Organization resolved
to eliminate polio in the Americas by 1990. In 1988, the WHA
resolved to eradicate polio worldwide by 2000 [16] and the Global
Polio Eradication Initiative (GPEI) was established in partnership
with UNICEF, the US Centers for Disease Control and
Prevention, and Rotary International; WHO was responsible for
overall management, program implementation, and fundraising.
In GPEI’s early years, with funding shortages and success of the
program in the Americas, research was not a priority. Neverthe-
less, limited applied research, driven by emerging operational
needs and gaps, led to advances in vaccine logistics, cold chains,
monitoring and evaluations, laboratory methodology, and surveil-
lance to detect cases of acute flaccid paralysis (AFP) [17].
Appreciation by GPEI of the need for intensified research grew
as new programmatic challenges and findings about polio virology
and epidemiology were encountered and posteradication questions
emerged. With awareness that additional approaches would be
essential if the target date for global interruption of transmission
was to be met, a Global Technical Consultative Group was
convened in 1996 to address challenges in eradication progress
[18]. Although polio due to type 2 wild poliovirus was eradicated
globally in 1999, cases and outbreaks due to types 1 and 3
continued. And, rather than marking global eradication, the year
2000 saw an unexpected outbreak of 21 polio cases in Hispaniola
caused by circulating vaccine-derived poliovirus [19]. Recognition
that vaccine-derived poliovirus could cause epidemics of AFP
reinforced the need for flexible research efforts to respond
expeditiously to emerging needs [19,20].
By 2004 [21], newer challenges to eradication in endemic
regions were recognized, including low tOPV efficacy in certain
populations, low herd immunity, and the participation of
vaccinated children in wild poliovirus circulation—collectively
considered as ‘‘failure-of-vaccine.’’ More frequent supplementary
immunization activity proved to be inadequate, highlighting the
need for research to elucidate virus transmission better and to
identify correlates of protection relevant at the population level.
Consequently, the WHO Polio Research Committee was
established in 2008 to provide a forum for addressing timely
research questions [22]; the Advisory Committee on Poliomyelitis
Eradication now provides oversight for research and application of
findings in program implementation [23].
In retrospect, anticipating research questions was difficult when
the path to polio eradication seemed straightforward. Today, 10
years past the original eradication goal, research has greatly
expanded, including ongoing research in operations, evidence-
based communication strategies to overcome socio-cultural or
Table 2. Research outputs that contributed to the eradication of smallpox and the regional elimination of polio and measles (or
outputs that are still undergoing evaluation or development): Lessons for the rejuvenated Malaria Eradication Program.
Research







Search for candidate antiviral
drugs with activity against Variola
(disappointing results in clinical
trials)
Identification of 3 serotypes;
Development of live and killed
virus vaccines; Modern monovalent
(type 1 or 3) and bivalent (types 1
and 3) vaccines; Sequencing of viral
isolates; Search for safe and
effective antiviral drugs
Live measles vaccine strains; IgM
measles antibody diagnostics; Oral
fluid-based diagnostic assays;
Sequencing of viral isolates to
obtain epidemiologic insights;
Measles H DNA vaccine (to prime
very young infants immunologically
so they can respond safely and
effectively to current live vaccine)
Biology of liver stage parasites; In
vitro culture of P. vivax; Sensitive,
simple, point of care diagnostics
to detect both symptomatic and
asymptomatic infections; Single
encounter radical cure and
prophylaxis drug; Vaccines to
interrupt transmission; New





administered by new methods of
delivery (e.g., Ped-O-Jet; bifurcated
needle); Evaluation of antiviral
agents (marboran, cytosine,
adenine arabinoside)
Immunogenicity of tOPV in
different settings; Immunogenicity
of monovalent and bivalent
vaccines; Duration of OPV
excretion by
immunocompromised subjects
Identification of a correlate of
protection (serum plaque
reduction neutralizing antibody);
Immune responses following initial
immunization and following
booster dose; Respiratory tract
administration of vaccine by
small particle aerosol or by
large droplet spray







strategy; Discovery of monkeypox
Impact of national and
subnational mass immunizations;
Identification of outbreaks due to
circulating vaccine-derived
polioviruses; Anthropological and
sociological studies to enhance
local support for vaccination
Identification of the ‘‘window of
vulnerability’’ in infants; Impact
of national and subnational mass
immunizations; Coupling mass
measles immunization with OPV
and antihelminthic administration
and bednet distribution
Improved methods to measure
malaria transmission in different
settings; Improved methods for
measurement of malaria
morbidity and mortality; Studies
of local vectors to identify points
of intervention
doi:10.1371/journal.pmed.1000405.t002
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religious belief-based resistance to vaccination [24], vaccines and
immunity, molecular epidemiology, mathematical modeling [25],
and a search for antivirals to curtail virus shedding.
The lesson learned from GPEI that research should accompany
elimination/eradication efforts from the outset applies directly to
the unsuccessful Malaria Eradication Program of 1955–1969. This
Program relied heavily on indoor spraying with residual
insecticides and detection of cases and treatment with chloroquine
as the primary interventions. Without a strong ongoing research
program within a flexible infrastructure, this program could not
respond adequately to the emergence of widespread mosquito
resistance to DDT and parasite resistance to chloroquine.
Measles
Measles, one of the most communicable of all infectious
diseases, exhibits an extraordinary propensity to reach susceptible
individuals even when they constitute only a small proportion of
the population [26]. In the prevaccine era, all children
experienced measles unless they lived in remote areas. [27]. The
clinical expression of infection approached 100% and led to life-
long protection against disease; the occasional individuals with
subclinical infection did not, apparently, transmit virus.
The case fatality rate of measles in malnourished infants in
developing countries exceeds 20% [26]. In 1999, measles was the
third most common cause of death among children ,5 years of
age in developing countries and the most common vaccine-
preventable cause. The gravity of measles disease and its
complications and the magnitude of the human and economic
tolls exacted are often insufficiently perceived by health profes-
sionals and the public: even in industrialized countries measles can
be severe with at least one case among every 1,000 proving fatal
[28].
In 1994, health ministers in the Americas committed to
eliminating measles from the Western Hemisphere [29], using a
triple pincer vaccination strategy consisting of a one-time ‘‘catch-
up’’ campaign targeting children 9 months through 14 years of age
(to interrupt wild-virus circulation), strengthened services to ‘‘keep-
up’’ routine measles vaccination in infants, and ‘‘follow-up’’
campaigns to maintain immunity in the preschool age group.
Indigenous transmission was interrupted by 2003, despite repeated
importations of measles from Europe and Japan [29].
Since 2000, considerable progress has been made worldwide in
diminishing mortality from measles through immunization
campaigns, particularly in sub-Saharan Africa [30]. When high
coverage is achieved, campaigns eliminate measles virus from the
community and indirectly protect young infants by diminishing
the force of infection. During field research in Togo in 2004 [31],
a national campaign to administer measles vaccine to all children
9–59 months of age was coupled with giving oral polio vaccine
(OPV), an oral antihelminthic, and insecticide-treated bednets;
.90% vaccination coverage was achieved. However, in some
African countries repetitive mass campaigns are proving difficult to
sustain and measles mortality in young children remains
problematic [32].
Research that helped interrupt transmission of measles in the
Western Hemisphere and to diminish measles mortality in Africa
includes studies of measles transmission in different populations,
improved diagnostic tests and sero-epidemiologic methods,
molecular finger printing to determine the geographic origin and
relatedness of measles virus isolates [33,34], and improved
methods of immunizing against measles using existing vaccines
[35]. Other research focuses on developing new vaccines to
immunize high-risk target groups (e.g., very young infants) who
cannot be effectively immunized with currently licensed measles
vaccines [36].
Lesson 2. The Reservoirs of Infection and Degree
and Specificity of Clinical Expression Influence
the Eradication Program
A feature common to smallpox, poliomyelitis, measles, and
Plasmodium falciparum and Plasmodium vivax malaria is that humans
constitute the sole reservoir of these pathogens; one need not
worry about animal or environmental reservoirs as sources of
reintroduction into human populations.
Smallpox
The discovery of human monkeypox exemplifies the impor-
tance of research to confirm the absence of a nonhuman reservoir
for diseases targeted for eradication, including malaria. The
monkeypox exanthem in humans resembles smallpox, albeit with
milder clinical symptoms and lower fatality rates. Accordingly,
during and after smallpox eradication in Africa there was concern
about the possible persistence of this orthopoxvirus virus in natural
settings [37]. Epidemiologic and laboratory research on monkey-
pox in enzootic areas of Africa [38–40] confirmed that it did not
spread easily in human populations and posed only a small threat
for becoming an endemic human illness [39,40], even though
some localized foci have been identified [37]. Recent reports of
human infections with the nonhuman primate parasite Plasmodium
knowlesi [41], raise concerns that, in certain ecologies, P. knowlesi
may increase in humans as P. falciparum disappears.
Polio
Smallpox and measles have ,100% clinical expression in
immunocompetent persons and asymptomatic chronic infections
do not occur. By contrast, many asymptomatic or mild cases of
poliovirus, P. falciparum, and P. vivax infection occur for every
clinical case. Early epidemiologic field research of polio identified
,150 infections that did not progress to paralysis for each case of
AFP [42]. Moreover, persons with B-cell immunodeficiencies can
chronically excrete vaccine polioviruses. These hidden reservoirs
make polio and malaria eradication fundamentally more difficult
than smallpox. Improved diagnostic tests are needed to identify
persons infected with polio and malaria, as cases become less
common.
Measles
Akin to the clinical confusion of measles with rubella and other
febrile exanthemata, clinical P. falciparum and P. vivax infections are
easily confused with many other febrile disorders. In another
parallel, immunocompromised individuals with measles giant cell
pneumonia may shed virus without having a rash and malaria-
immune individuals may have parasites in their blood in the
absence of clinical symptoms and may act as infectious source for
the mosquito vector. The most vexing issue in malaria elimina-
tion/eradication is P. vivax hypnozoites, a form of the parasite
resident in the liver that creates persistent (for years), silent
infection that is nonresponsive to standard treatment for clinical
malaria. The only current drug effective against P. vivax
hypnozoites is the 8-aminoquinoline primaquine.
To summarize, the lesson learned here is that malaria
eradication will be facilitated by improved diagnostics that can
detect mild and asymptomatic blood infections and that can
identify asymptomatic persons harboring P. vivax hypnozoites. A
corollary lesson is that high priority should be placed on
developing new, well-tolerated drugs to treat persons with latent
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P. vivax infection, particularly individuals genetically deficient in
glucose 6-phosphate 1-dehydrogenase (who develop hemolytic
anemia when treated with primaquine). malERA’s concept of
developing a Single Encounter Radical Cure and Prophylaxis
(‘‘SERCaP’’) drug, if successful, would accomplish that.
Lesson 3. The Critical Role of Surveillance
A theme common to the smallpox, polio, and measles
eradication/elimination programs is the critical role that surveil-
lance has played in every phase, including quantification of the
burden at the onset of the program; monitoring progress of the
program at local, national, and global levels; intensive searches for
the last cases and infected persons; and documentation of the
interruption of transmission. The critical role of surveillance
necessitated research to develop new epidemiologic surveillance
systems for all three diseases and, for measles and polio, sero-
epidemiologic methods, tests to identify asymptomatic carriers,
and molecular methods to establish the geographic source and
relatedness of isolates from outbreaks and clusters over different
time periods. This lesson is directly applicable to the Malaria
Eradication Program, which will need to assure that adequate
surveillance methods and techniques are in place to monitor the
effectiveness of the program.
Smallpox
The magnitude of the smallpox problem was largely unknown in
1959, despite the International Health Regulation that all smallpox
cases be reported. Finding and controlling outbreaks quickly was
essential for the containment strategy. Accordingly, within each
country, all health care facilities were asked to provide a weekly report
about smallpox cases. Every 3 weeks, international surveillance
reports were prepared and widely distributed that charted progress by
country, informed new findings through research, and recommended
changes in strategy. These reports and special national reports
developed by some countries were invaluable in rapidly informing all
concerned about progress in the program and in conveying new
discoveries and new directions for the program.
Another aspect of smallpox eradication that might be relevant
to the malaria elimination/eradication program is the rigorous
program of certification of absence of smallpox that began in the
1970s and that was intensified until the WHA confirmed global
eradication in 1980. Tens of thousands of specimens from persons
with ‘‘fever and rash’’ were collected with well-publicized rewards
being offered to persons reporting any patient with confirmed
smallpox.
Polio
Pathogens other than polioviruses also cause AFP. A measure of
the quality of polio surveillance is the adequacy of detection of
AFP cases and the proportion of cases from whom stool specimens
are obtained for virological analysis. Moreover, paralytic polio
cases represent only the tip of the epidemiologic iceberg. Thus,
polio shares with malaria the attribute that many persons
harbouring infection will be clinically unsuspected. In the context
of eradication, all infected individuals are epidemiologically
important [43]. Consequently, malERA has rightly given high
priority to the development of improved tests to detect clinically
typical, mild and asymptomatic Plasmodium infections and to assess
the extent of transmission.
Measles
Measles outbreaks must be detected and curtailed to limit
transmission following importations. For outbreak detection,
specific, practical, and rapid measles diagnostic tests are needed.
Research developed such tests and the strategies to use them.
Serum specimens and either urine or nasopharyngeal samples are
obtained from suspect measles cases and, as appropriate, from
contacts [44]. The serum is tested for measles-specific immuno-
globulin M (IgM) antibodies indicative of acute infection. A
noninvasive alternative involves collecting oral fluid [45]. Measles
virus in urine or nasopharyngeal specimens is detected by culture
or reverse transcriptase PCR. Unfortunately, these tests are not
suitable for point-of-care diagnosis. A simple, rapid, inexpensive,
sensitive, and specific point-of-care diagnostic for measles will
facilitate eradication efforts. Similarly, malERA has identified the
need for a sensitive, specific, and inexpensive diagnostic test
amenable to use in the field.
Lesson 4. Molecular Epidemiology
Research fostered by the viral disease eradication/elimination
programs has shown how molecular tools add precision to
surveillance. The molecular epidemiologic evaluation of plasmo-
dial parasites will be similarly helpful, particularly in the later
stages of a Malaria Eradication Program; research in this area
should be encouraged.
Smallpox
Genetic analysis of isolates of orthopoxviruses from patients and
animals has shown the important differences among smallpox
viruses (Variola major and V. minor), monkeypox, and vaccinia that
are useful for surveillance [46,47].
Polio
Partial genomic sequencing of all wild poliovirus isolates is
undertaken to determine genetic relatedness. Each 1% difference
between two isolates correlates with approximately 1 year of
undetected circulation between the specific chains of transmission.
A difference of .1.5% suggests undetected past transmission,
thereby identifying inefficient surveillance systems. In addition,
timely genome sequencing and construction of phylogenic trees
make it possible to assess eradication progress through genetic
cluster elimination, to identify human reservoirs, to differentiate
indigenous from imported viruses, to identify surveillance gaps
(through isolates without recent parental strains), and to identify
vaccine-derived polioviruses and quantify their period of circula-
tion [20,48].
Measles
Genotyping of measles viruses allows identification of the
geographic origin of imported viruses/cases and provides a means
of tracking epidemiologic relationships among cases in the same or
separate outbreaks [33,34].
Lesson 5. The Pivotal Role of Vaccines as a Tool
for Disease Eradication
The eradication of smallpox and of type 2 poliovirus infection
globally, and the elimination of polio and measles from various
regions and countries was achieved using vaccines as the primary
intervention tool. As malaria transmission diminishes, other
interventions (e.g., vector control, insecticide-impregnated bed-
nets, new drugs, etc.) will surely play critical roles, but the lesson
from the viral disease programs is that vaccines that interrupt
transmission could play a critical role in helping to eradicate
malaria.
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Smallpox
Until the 1960s, smallpox vaccine was typically a liquid product
of suboptimal potency, readily inactivated by heat within a few
days. Industrial process research developed a method for
producing heat-stable, freeze-dried smallpox vaccine [4] that
could withstand temperatures of 37uC for at least 1 month. With
technical assistance from industrialized countries, .80% of
lyophilized smallpox vaccine of acceptable quality was being
manufactured in developing countries within 6 years of the
eradication program starting. Having smallpox vaccine that did
not require refrigeration was of immeasurable practical impor-
tance in the field [11].
At the onset of the eradication program, age-old, traditional
techniques of scratching or pressing the vaccine into the skin
frequently failed to immunize. New vaccination techniques were
introduced that permitted more rapid and effective inoculations.
Jet injectors were perfected and field tested that could vaccinate
hundreds of people per hour. By 1971, the injectors were
superseded by a simple two-pronged (bifurcated) needle [49].
WHO tested these needles for a unique multiple-puncture
vaccination technique. Successful vaccination responses ap-
proached 100%, less vaccine was required for each vaccination,
instruction in vaccination required only ,15 minutes, and the
needles could be sterilized and reused repeatedly. In Africa and
Asia, with a good working rapport with villagers and their leaders,
a vaccinator with bifurcated needles could average 500 vaccina-
tions per day. To measure vaccination coverage and vaccine
‘‘take’’ rates (vesicle or early crusting lesion on the skin 1 week
after vaccination), a sample survey of villagers was routinely
checked [50].
The impact of the bifurcated needle in improving the logistics of
smallpox vaccination was immense. A possible analogous situation
for malaria eradication may arise with the need to identify
practical ways to deliver the promising attenuated sporozoite
vaccines that are under development [51–53].
Smallpox field research may also provide lessons for malaria
eradication efforts. For example, smallpox outbreak containment
teams that were deployed to the field to determine how smallpox
outbreaks spread and to vaccinate contacts and neighbours of
patients discovered that smallpox did not spread as rapidly and
widely as textbooks described. Chains of smallpox transmission
could be broken in most areas by the surveillance-containment
approach, and this approach was soon given priority over mass
vaccination. Similarly, field research showed that smallpox vaccine
protection lasted at least 10 years, not 3–5 years as traditionally
thought. Recent research on immunologic memory has established
the basis for the long-lived protection [54].
Polio
Research in the 1950s created two polio vaccines—an oral
approach based on three live attenuated poliovirus strains
(originally administered sequentially but subsequently licensed as
a trivalent formulation) [43], and an intramuscular vaccine
consisting of three formalin-inactivated polioviruses. Although
both vaccines drastically diminished polio cases in industrialized
countries, tOPV was selected as the lynchpin of the GPEI, being
less expensive and easier to administer. Failure to achieve the goal
of polio eradication by 2000 was attributed to inadequate
vaccination coverage and research recommendations were pri-
marily operational in nature. However, it has since become
apparent that there are major gaps in our understanding of
immune mechanisms. Current research priorities include the
development of surrogate measures of mucosal immunity and
interventions to boost and prolong immunity, and the determina-
tion of the relationship between waning immunity and virus
circulation. Research is also addressing the observation that tOPV
in infants appears to be less immunogenic in some areas in India
than elsewhere [55–58].
Recognizing that type 2 polio has been eradicated since 1999
but that type 1 and 3 disease continues, an accelerated
collaborative research and development effort undertaken with
industry resulted in the licensure and use of monovalent type 1 and
3 vaccines and a novel bivalent (types 1 and 3) OPV formulation
[23,59]. Deleting the more immunogenic and dominant type 2
virus that interferes with responses to the type 1 and 3 viruses
allows enhanced serological responses to types 1 and 3. The
bivalent vaccine has now become the preferred tool in supple-
mental immunization campaigns.
Measles
Cell culture propagation of measles virus in 1954 was followed
by development of the first generation of parenteral live measles
vaccines, which were protective but associated with unacceptably
high rates of febrile reactions. Further research yielded the current
well-tolerated vaccines. Inactivated measles-virus vaccines had also
been licensed in 1963 based on safety, immunogenicity, and short-
term efficacy data [60]. However, immunity was short-lived;
postlicensure surveillance revealed that some vaccine recipients
developed a syndrome of atypical measles when subsequently
exposed to wild measles virus [61,62]. Accordingly, inactivated
measles vaccine use was discontinued by 1967.
The fall in measles cases following introduction of the first
generation measles vaccine in the United States in 1963 prompted
epidemiologists to predict that measles could be eliminated
country-wide by 1967, if vaccine could be administered routinely
to infants and to susceptibles at school entry and if surveillance and
epidemic control could be strengthened [63]. Although measles
incidence fell by .90% by 1967, it took 26 more years until
indigenous transmission was interrupted in the United States. This
achievement required a routine second dose of vaccine before
school entry and a reduction in imported infections consequent to
enhanced measles control elsewhere [64].
By 1999, most measles deaths were occurring among children in
the Indian sub-continent and sub-Saharan Africa, despite
recommendations that measles vaccine should be given routinely
to infants,9 months of age. A notable proportion of these measles
deaths clustered among young infants during their ‘‘window of
vulnerability’’ (approximately 4–9 months of age) [65], when
falling titres of maternally derived measles antibodies no longer
protect against disease but nevertheless interfere with successful
immunization. Reports that immunogenicity could be enhanced in
infants ,6 months of age by administering high-titre vaccine
generated optimism that a solution to protecting young infants
might be at hand [66]. However, this approach was soon
abandoned when long-term follow-up revealed unexplained
increased mortality in female children [67].
Three new research efforts are addressing ways to protect young
infants in developing countries, to provide adjunct tools for
measles elimination [68]. The first involves repetitive follow-up
mass immunization of children with the existing vaccines to
indirectly protect young infants [30]. The second involves clinical
trials to allow licensed vaccine to be administered to the
respiratory tract by small particle aerosol, thereby making mass
immunization simpler and safer [35]; clinical research has shown
that vaccine delivered to the nasal mucosa by large droplet spray is
ineffective [69]. The third research effort has resulted in
development of a candidate measles DNA vaccine encoding the
hemagglutinin (H) antigen of measles virus [36].
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Lesson 6. Modes of Transmission and Modeling
Smallpox and measles viruses are transmitted by the respiratory
route (droplets/aerosol), while polio is mainly transmitted by the
fecal-oral route in developing countries. Although modeling
played no role in smallpox eradication, it has been extremely
useful in the GPEI as a valuable epidemiologic research tool, for
addressing economic issues, and for providing insight into future
programmatic options [25]. Modeling research is currently
addressing the risks of virulent vaccine-derived poliovirus that
may be chronically shed by immunodeficient individuals and from
circulating vaccine-derived poliovirus, after OPV is withdrawn
posteradication [70]. Similarly, measles was one of the first
infectious diseases studied with models, and models are now being
used to elucidate better the epidemiologic behaviour of measles
and predict the effect of interventions [71,72]. Although the ability
to generalize from models is debated [73], there is consensus that
the quality of input data is steadily improving, even as the
epidemiology of measles is changing globally.
Malaria, spread by female Anopheles mosquitoes, has a more
complex transmission than these viral infections, which allows
transmission to be decreased by targeting to control the vector or
vector-host contact, as well as by changing susceptibility of the
human host. Modeling is therefore particularly important to
predict the effect of various interventions used independently and
in unison on the transmission of malaria. It can also identify ways
to minimize and delay parasite resistance to drugs [74] and should
be an integral part of any malaria elimination/eradication
program, as recognized by malERA.
Lesson 7. Sociological, Anthropological, Cultural,
and Religious Issues
Another lesson for malaria from the viral eradication/
elimination programs is the important role that socio-cultural,
religious, and local political factors play in public perception of the
disease and of the main intervention tools of the eradication
program; these factors can accelerate or impede eradication
efforts. It is prudent to support research on these issues and on
improving ways to communicate effectively with local populations.
In this area of research, one size does not fit all.
Smallpox
Smallpox was a severe, commonly lethal infection that often left
survivors scarred and occasionally blind. Thus, in most endemic
areas smallpox was recognized and feared by the population.
Aversion to vaccination was not, therefore, a major impediment
during the Smallpox Eradication Program.
Polio
As paralytic polio (a relatively rare disease) diminished in
incidence and became less of a threat, it became increasingly
difficult to motivate populations to continue support for eradica-
tion activities. The GPEI and public health authorities worldwide
became concerned by events in Nigeria in 2003–2004 that set
polio eradication back there and in much of Africa. In late 2003,
several states in northern Nigeria refused to participate in national
mass immunization campaigns. Religious and political leaders in
three states counseled parents against having their children
immunized, preaching that the vaccine was contaminated with
antifertility hormones, HIV, and cancer-inducing agents [75].
Only after a Nigerian team (including members from the affected
states) visited a manufacturer of OPV in Indonesia, a Muslim
country, did the state governments accept that OPV was safe [75].
Confidence was restored and progress in polio eradication has
since been achieved in Nigeria and elsewhere in Africa [76]. The
lesson here is that evidence-based communication strategies must
be carefully planned and implemented to overcome resistance to
vaccination that originates from socio-cultural or religious beliefs
[24,77].
Measles
A potential barrier to global eradication of measles is the poor
measles vaccine coverage in many industrialized countries (in
Europe and Japan) where strong antivaccine movements specif-
ically target the measles vaccine. Without supporting scientific
evidence, these antivaccine groups indict measles vaccine as a
cause of autism and other chronic disorders. Continuing measles
transmission in such industrialized countries maintains a reservoir
that imperils elimination efforts in other countries. Further
research in communications, anthropology, and sociology must
be undertaken to find ways to counteract the antivaccine
propaganda and increase the acceptance of measles vaccine.
Lesson 8. The Concept of ‘‘The Last Kilometre’’
A cross-cutting theme among the smallpox, polio, and measles
eradication/elimination programs is that interruption of the last
vestiges of transmission in a country or region is problematic and
requires the allocation of as many resources as the early stages that
achieved a 90%–99% reduction in incidence. Therefore, inter-
ventions often need to be modified, sometimes drastically, to
complete the job of elimination.
Similarly, in the future, the final stages of the Malaria
Eradication Program will likely confront barriers as complex,
demanding, and refractory as ones encountered early in the
program. Some will be resolvable only through directed, focused
research. Thus, the rejuvenated Malaria Eradication Program
should support a flexible research infrastructure that can adapt to
the challenges.
Lesson 9. Posteradication Agendas
The final lesson learned from the viral disease eradication
programs is that discussion of posteradication scenarios, problems,
and potential solutions must begin at the onset of the programs.
Focused research can find early solutions for some posteradication
issues. In the case of smallpox, affirmation of the eradication of
smallpox was followed by a discontinuation of routine vaccination
globally. The only way that smallpox disease can occur anew is if
nefarious individuals with access to virus undertake a deliberate
bioterror release. In the case of polio, however, since 2005, GPEI
has been grappling with posteradication questions of use of OPV,
the quandary of vaccine-derived poliovirus persistence, laboratory
destruction and containment of poliovirus stocks, surveillance
needs, vaccine compositions, and response strategies. These
questions have become the drivers of a research agenda [78].
For measles, the major posteradication dilemma will be whether to
continue routine immunization with the live measles vaccine.
Given that in some industrialized countries, certain groups in the
population view measles vaccine with more suspicion than the wild
virus, it might be necessary to develop and utilize an alternative
nonliving type of measles vaccine [36].
Concluding Comments
Nine cross cutting lessons have been provided by these three
vaccine-dependent eradication and elimination programs of viral
diseases in which research was integral to guide program activities.
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These lessons will be useful to the revitalized Malaria Eradication
Initiative. Research played a critical role in the Smallpox
Eradication Program and is still contributing critically to the
GPEI and measles elimination and mortality control programs.
Despite having tools for primary prevention, considerable research
has been essential to address geographic variations in the force of
transmission of smallpox, polio, and measles and to adjust the
tactical use of the preventive tools.
The ecology and epidemiology of malaria are far more complex
than the ecology and epidemiology of these viral infections. Thus,
if a global Malaria Eradication Initiative is revived, from the outset
the Malaria Eradication Research Agenda should be incorporated
as an essential component. Malaria eradication proponents should
understand the importance of combining operational and research
issues. Over time in successful elimination initiatives, the best
researchers will see their ideas implemented and the best
implementers will continue to ask what research could further
improve operations.
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